Todd Watanabe Sells $139K of Arcutis Biotherapeutics Inc (ARQT) — SEC Form 4, Nov 04, 2026

Open-Market Net Sale · SEC Form 4

−$139,466

2 Insiders Selling

Equity position changed by -0.5%

Reporting Owner

Todd Watanabe

CEO

TXN 2026-11-02 · FILED 2026-11-04

Equity Position 946K sh 950,337 → 945,960

Equity Change -0.5% shares held after vs before

Insider Cluster 2 selling within 30 days — view cluster

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Arcutis Biotherapeutics Inc

ARQT CIK 0001787306

All Arcutis Biotherapeutics Inc insider activity

Filing Date: 2026-11-04
Report Date: 2026-11-04
Accession No.: 0001628280-26-070381
Accepted At: 2026-11-04 23:38 UTC

Reporting Owner

Name	Relationship
Todd Watanabe CIK 0001801061	Director CEO

Todd Watanabe at Arcutis Biotherapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $3,292,263

More from this insider at Arcutis Biotherapeutics Inc

2026-08-06	Sell	-$114,261	View
2026-05-06	Sell	-$74,893	View
2026-03-04	Sell	-$940,528	View
2026-02-05	Sell	-$505,710	View
2025-11-24	Sell	-$1,517,405	View

All filings by this insider at Arcutis Biotherapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1 F2	2026-11-02	S - Sale	4,377 D	$31.86	-$139,466	712,826	Direct

Non-Derivative Holdings

Title	Shares Held	Ownership
Common StockF3	25,410	Indirect By Trust
Common StockF4	25,410	Indirect By Trust
Common StockF5	57,358	Indirect By LLC
Common StockF6	124,956	Indirect By Trust

Footnotes (6)

F1: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. Show more
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $31.57 to $32.23, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Show more
F3: The securities are held of record by The John Franklin Watanabe Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Show more
F4: The securities are held of record by The Anderson Prest Watanabe Irrevocable Trust, of which the Reporting Person is the trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Show more
F5: The securities are held of record by Watanabe Ventures, LLC, of which the Reporting Person is the Chief Operating Officer. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Show more
F6: The securities are held of record by The Watanabe 2016 Irrevocable Trust, of which the Reporting Person's children are beneficiaries. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Show more